September 26, 2026 – Aspartes Pharmaceuticals Announces Completion of Phase 1 Clinical Study Evaluating ASP-001 ODT Formulations.

Contact
← Back to News
Press Release
April 19th, 2026

Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Published
April 19th, 2026
Share this release
Media contact

Denny Medjedovic
info@aspartes.com

All news
More news

Latest Press Releases

View all news
August 10, 2026

Aspartes Pharmaceuticals Announces FDA Orphan Drug and Rare Pediatric Disease Designations for ASP-001 for the Treatment of Alternating Hemiplegia of Childhood

READ MORE